Therapeutic Potential of Centella asiatica Linn in Oral Submucous Fibrosis: A Short Communication
ZM01-ZM02
Correspondence
Dr. Pallavi Prakash Channe,
Associate Professor, Department of Oral Medicine and Hospital, Dr. D. Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri-411018, Pune, Maharashtra, India.
E-mail: pallavi.channe@dpu.edu.in
Oral Submucous Fibrosis (OSMF) is a chronic progressive disease characterised by fibrosis of the oral mucosa, leading to restricted mouth opening and difficulties in speech and swallowing. Modern science has explored a variety of surgical and medicinal therapy approaches, but the outcomes are often unsatisfactory due to recurrence, side effects, and, at times, a worsening of the condition due to fibrosis. Adjuvant therapies, especially antifibrotic herbs, are urgently needed for better treatment outcomes in OSMF. Centella asiatica Linn, also known as Indian pennywort or Asiatic pennywort, has shown potential therapeutic benefits in the treatment of OSMF. This short communication summarises studies indicating that Centella asiatica Linn has the potential to act as an antifibrotic agent, as it downregulated most fibrotic markers in both in-vivo and in-vitro set-up.